Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Romina QuerciaDaniel Kuritzkes

Abstract

Innovation in medicine is a dynamic, complex, and continuous process that cannot be isolated to a single moment in time. Anniversaries offer opportunities to commemorate crucial discoveries of modern medicine, such as penicillin (1928), polio vaccination (inactivated, 1955; oral, 1961), the surface antigen of the hepatitis B virus (1967), monoclonal antibodies (1975), and the first HIV antiretroviral drugs (zidovudine, 1987). The advent of antiretroviral drugs has had a profound effect on the progress of the epidemiology of HIV infection, transforming a terminal, irreversible disease that caused a global health crisis into a treatable but chronic disease. This result has been driven by the success of antiretroviral drug combinations that include nucleoside reverse transcriptase inhibitors such as lamivudine. Lamivudine, an L-enantiomeric analog of cytosine, potently affects HIV replication by inhibiting viral reverse transcriptase enzymes at concentrations without toxicity against human polymerases. Although lamivudine was approved more than 2 decades ago, it remains a key component of first-line therapy for HIV because of its virological efficacy and ability to be partnered with other antiretroviral agents in traditional and n...Continue Reading

References

Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S L DoongY C Cheng
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·B A LarderD J Purifoy
Dec 1, 1994·Antimicrobial Agents and Chemotherapy·J L MartinJ E Reardon
May 1, 1997·Antimicrobial Agents and Chemotherapy·S M DalugeT A Krenitsky
Feb 16, 1999·Clinical Pharmacokinetics·M A JohnsonG E Pakes
Mar 20, 2001·JAMA : the Journal of the American Medical Association·S StaszewskiUNKNOWN CNAAB3005 International Study Team
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Katharina WolfBarbara Schmidt
Nov 26, 2003·The Journal of Infectious Diseases·Franck S RousseauUNKNOWN FTC-102 Clinical Trial Group
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edwin DeJesusUNKNOWN EPV20001 International Study Team
Sep 29, 2004·The Journal of Biological Chemistry·Tracy L DiamondBaek Kim
Oct 16, 2004·Expert Review of Anti-infective Therapy·Mark A Wainberg
Dec 4, 2004·AIDS·Constance A BensonUNKNOWN FTC-303/350 Writing Group
Jan 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Judith C ShlayUNKNOWN Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas B CampbellDaniel R Kuritzkes

❮ Previous
Next ❯

Citations

Nov 15, 2019·Clinical Pharmacology in Drug Development·Teodora Pene DumitrescuKimberly Adkison
Feb 11, 2020·Sudebno-meditsinskaia ekspertiza·E A IllarionovaYu A Gonchikova
Feb 19, 2020·Expert Review of Anti-infective Therapy·Arturo CicculloSimona Di Giambenedetto
Jun 13, 2020·Frontiers in Oncology·Giovanni Barillari
Jan 14, 2020·HIV Medicine·O T StirrupUNKNOWN UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort
Jun 9, 2020·Expert Opinion on Drug Metabolism & Toxicology·Piyanuch WongananKiat Ruxrungtham
Jul 8, 2020·International Journal of Molecular Sciences·Giovanni Barillari
Oct 12, 2020·Drugs·Andrew MujugiraJessica E Haberer
Aug 14, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Trevor A CrowellUNKNOWN AFRICOS Study Group
Jun 27, 2019·Infectious Disease Clinics of North America·Sean G KellyBabafemi O Taiwo
Sep 17, 2019·Biomaterials·Nathan SmithBenson Edagwa
Nov 11, 2020·Genome Génome / Conseil National De Recherches Canada·Massara Camara-CisseHenri Chenal
Jun 29, 2021·Statistics in Medicine·Zonghui Hu
Jul 31, 2021·International Journal of Nanomedicine·Ran ChenJingqing Zhang
Jul 22, 2021·Pharmacology Research & Perspectives·Siennah R MillerNathan J Cherrington
Jul 22, 2020·Journal of Proteome Research·Minchen ChienJingyue Ju

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02831673
NCT02831764

Software Mentioned

PADDLE

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.